NCT04970940View on ClinicalTrials.gov

The Drug-drug Interaction Study of AJU-A51R1 and AJU-A51R2

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 2, 2020

Primary Completion Date

October 7, 2020

Study Completion Date

December 31, 2020

Conditions
T2DM (Type 2 Diabetes Mellitus)
Interventions
DRUG

Treatment A

AJU-A51R1: Farxiga 1 Tab., Q.D., single dose, for 5 days

DRUG

Treatment B

AJU-A51R2: Trajenta 1 Tab., Q.D., single dose, for 11 days

DRUG

Treatment C

AJU-A51R1 1 Tab. and AJU-A51R2 1 Tab., Q.D., co-administration for 5 days

Trial Locations (1)

Unknown

Min-gul Kim, Jeonju

All Listed Sponsors
lead

AJU Pharm Co., Ltd.

INDUSTRY

NCT04970940 - The Drug-drug Interaction Study of AJU-A51R1 and AJU-A51R2 | Biotech Hunter | Biotech Hunter